Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mast Therapeutics touts interim data from pulmonary hypertension study

November 4, 2016 By Sarah Faulkner

Mast touts interim data from pulmonary hypertension studyMast Therapeutics (NYSE:MSTX) touted interim data from a Phase II study of its AIR001 candidate in patients with pulmonary hypertension (PH) and PH associated with heart failure with preserved ejection fraction. Positive interim results from the ongoing trial were published in the Journal of Clinical Investigation.

The San Diego-based company enrolled 50 patients to study its nebulized inhaled nitrite and interim results showed that AIR001 significantly decreased pulmonary, right atrial and pulmonary capillary wedge pressures. The change was most prominent in patients with PH associated with heart failure with preserved ejection fraction.

The treatment was well-tolerated and the researchers did not note any major safety concerns, which satisfied the primary safety outcome of the study. There were also no significant decreases in peripheral oxygen saturation nor increases in methemoglobin levels above 5%, according to the company.

“The results observed to date are important as they demonstrate that AIR001 can significantly lower right atrial pressures, pulmonary artery pressures, and pulmonary artery occlusion pressures, as well as improve pulmonary artery compliance,” chief medical officer Edwin Parsley said in prepared remarks. 

“These data are consistent with results we saw in a separate investigator-sponsored Phase 2 study of AIR001 in HFpEF earlier this year and serve as a further step in validating AIR001 and establishing its potential clinical utility in HFpEF,” CEO Brian Culley added. “We look forward to advancing AIR001 in this area of high unmet medical need for which there is no FDA-approved therapy available. In addition to full results from this 50-patient study, the 100-patient  ‘INDIE-HFpEF’ study of AIR001 also is expected to complete enrollment and announce top-line results next year. We believe these are important value-creating studies which convincingly demonstrate the potential for clinical utility of AIR001 in HFpEF and potentially other settings.”

Filed Under: Cardiovascular, Clinical Trials, Featured Tagged With: Mast Therapeutics

IN CASE YOU MISSED IT

  • Aptar wins FDA clearance for ready-to-use seizure treatment device
  • Proteus Digital Health restructuring amid reported funding woes
  • Dexcom warns of potential danger to European app users
  • Report: 3M may sell off its drug-delivery business for $1 billion
  • W.L. Gore officials think they can spur insulin delivery system innovation
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS